BMP9 Agonist Therapy for Gynecological Cancer Metastasis Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gynecological cancers are often diagnosed at advanced stages due to subtle symptoms, leading to significant metastasis, and existing treatments struggle to effectively target anoikis resistance in tumor cells, which is crucial for metastasis suppression.
Innovation Solution
Administering BMP9 or its agonist to subjects with cancer, particularly gynecological cancer, to suppress metastasis by enhancing anoikis and reducing tumor growth, potentially combined with anti-cancer compounds like paclitaxel or cisplatin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are used to treat gynecological cancer, then tumor growth is inhibited, but metastasis suppression is insufficient due to anoikis resistance in tumor cells
Solution Approach 1:
The patent changes the biochemical parameter state of tumor cells by administering BMP9 or its agonists, which modifies the cellular response to anchorage independence. This transforms the parameter of anoikis sensitivity from resistant to sensitive, thereby suppressing metastasis without affecting the primary tumor treatment efficacy
Solution Approach 2:
BMP9 acts as an intermediary substance that mediates between the extracellular environment and tumor cell survival mechanisms. It specifically targets the anoikis pathway through SMAD1/5/8 signaling, serving as a bridge to restore apoptotic responses in detached tumor cells while leaving conventional chemotherapy mechanisms intact
2Reliability
If BMP9 or agonist is administered to enhance anoikis and suppress metastasis, then metastatic potential is reduced, but treatment complexity increases
Solution Approach 1:
BMP9 exhibits multi-functionality by simultaneously addressing multiple aspects of cancer progression: it suppresses metastasis through anoikis induction, works synergistically with conventional chemotherapy agents, and can be administered via existing pharmaceutical routes. This universal approach consolidates multiple therapeutic goals into a single agent
Solution Approach 2:
The patent merges BMP9 therapy with conventional chemotherapy regimens, creating a combined treatment approach where BMP9 enhances the anti-metastatic effects while chemotherapy addresses primary tumor control. This combination integrates two therapeutic mechanisms into a unified treatment strategy
Data Source
AI summary
Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.